این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Archives of Breast Cancer، جلد ۱۲، شماره ۴، صفحات ۴۹۴-۵۰۱
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Predictive Value of Inflammatory Indexes as Biomarkers of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer: Inflammatory indexes and NAC in BC
چکیده انگلیسی مقاله Background: Breast cancer remains the most common cancer in women worldwide. Treatment has evolved into multimodal approaches, with pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) serving as a key prognostic marker. The aim of this study was to evaluate the value of inflammatory markers in predicting pCR to NAC in breast cancer. Methods: This cross-sectional study of 74 patients with breast cancer who underwent NAC followed by surgery included demographic, tumor, and immune-inflammatory marker data. Receiver operating characteristic curve analysis and the Youden index were used to determine optimal cutoff values. Univariate and multivariate logistic regression assessed associations between markers and pCR, adjusting for tumor stage, human epidermal growth factor receptor 2 (HER2), and estrogen receptor (ER) status. Results: Our multivariate analysis identified the pan-immune-inflammation value (PIV), HER2 status, and ER status as significant independent predictors of pCR. PIV (OR, 4.28; 95% CI, 1.59–16.88) remained significant among inflammatory markers, while the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) did not. HER2-positive (OR, 7.45; 95% CI, 2.30–24.15) and hormone receptor (HR)–negative (OR, 7.02; 95% CI, 2.63–18.70) statuses were also strongly associated with pCR. Conclusion: PIV is a robust predictor of pCR in patients with breast cancer receiving NAC, offering a comprehensive reflection of the immune-inflammatory state. Incorporating PIV with tumor-specific markers (e.g., receptor status, Ki-67, grade) may enhance treatment stratification. Further validation in diverse cohorts is warranted.
کلیدواژه‌های انگلیسی مقاله breast neoplasms, biological markers, inflammation, treatment outcome
نویسندگان مقاله | Vedad Dedic
Clinical Center University of Sarajevo, Department of general, abdominal and glandular surgery


| Timur Ceric
Clinical Center University of Sarajevo, Department of Oncology, Sarajevo, Bosnia and Herzegovina


| Sadat Pusina
Clinical Center University of Sarajevo, Department of General, Abdominal and glandular surgery Sarajevo, Bosnia and Herzegovina


| Mirhan Salibasic
Clinical Center University of Sarajevo, Department of General, Abdominal and glandular surgery Sarajevo, Bosnia and Herzegovina


| Nejra Selak
Clinical Center University of Tuzla, Department of Pathology, Tuzla, Bosnia and Herzegovina


| Emir Bicakcic
Clinical Center University of Sarajevo, Department of General, Abdominal and glandular surgery Sarajevo, Bosnia and Herzegovina


| Nedim Katica
Clinical Center University of Sarajevo, Department of Plastic and Reconstructive Surgery, Sarajevo, Bosnia and Herzegovina
نشانی اینترنتی https://archbreastcancer.com/index.php/abc/article/view/1137
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi) 10.32768/abc.4129785063-927
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات